BRAF V600E Colon Cancer: Targeted Therapy Before Chemotherapy Ever Starts
The targeted regimen that works best for this mutation was only ever tested after chemotherapy — and this patient may not be a good candidate for the chemotherapy the label assumes comes first.
V.P., a 75-year-old man, ran a small hardware store for four decades before handing it to his son two years ago, and still comes in most mornings "to make sure nobody's rearranging the fasteners aisle wrong." He was worked up for two months of vague abdominal discomfort and a ten-pound weight loss he'd chalked up to "eating less since retiring," and colonoscopy found a right-sided mass; staging CT showed peritoneal nodules alongside the primary. Molecular testing confirmed a BRAF V600E mutation — a finding that changes both his prognosis and his treatment options substantially, since BRAF-mutant colorectal cancer behaves more aggressively and responds less durably to standard chemotherapy than BRAF-wild-type disease. He also carries real frailty markers beyond his age alone: a recent 12% weight loss, a Charlson comorbidity burden from atrial fibrillation and stage 3 chronic kidney disease, and a formal geriatric assessment that flagged him as intermediate-to-vulnerable, not robust.
Encorafenib plus cetuximab, the regimen BEACON CRC established as superior to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer — longer overall survival, higher response rate, and a materially better tolerability profile than triplet chemotherapy — was studied and approved specifically in patients who had already received one or two prior lines of therapy, not as an upfront regimen. The aggressive natural history of BRAF-mutant disease has led many oncologists to favor maximal upfront cytoreduction with FOLFOXIRI plus bevacizumab instead, reasoning that this biology doesn't tolerate a cautious first step. But FOLFOXIRI's toxicity was established in fit, mostly younger trial populations, and V.P.'s own frailty profile puts him well outside where that regimen has actually been shown to be both tolerable and beneficial — raising a real question of whether following the aggressive-biology logic toward the more aggressive regimen actually serves a patient this regimen's own evidence base doesn't represent.
Geriatric oncology clinic, treatment planning visit
BRAF V600E-mutant colorectal cancer has a genuinely worse natural history than wild-type disease, and the standard response to that has been maximal upfront cytoreduction — FOLFOXIRI plus bevacizumab. BEACON CRC (Kopetz et al., NEJM 2019) validated encorafenib plus cetuximab specifically as a later-line regimen, after prior chemotherapy, and I'd be cautious about moving a regimen ahead of the position it was actually proven in.
I hear the sequencing argument, but FOLFOXIRI's toxicity data come from trial populations that look nothing like V.P. — fit, mostly under 70, without his weight loss or renal impairment. His own geriatric assessment puts him in the vulnerable range, where triplet chemotherapy carries a real risk of a toxicity event that could end his candidacy for any further treatment at all, targeted or otherwise. Encorafenib and cetuximab showed a meaningfully better tolerability profile in BEACON CRC's own population, and I don't think "it was tested later" should outweigh "it's the regimen actually suited to this patient's physiology."
The aggressive-biology argument assumes aggressive treatment is what a vulnerable patient's body can actually deliver — for V.P., I don't think that assumption holds.
There's a version of this that doesn't require picking a side outright. A de-escalated backbone — FOLFOX or FOLFIRI alone, without the third cytotoxic agent, with or without bevacizumab — gives real disease control without exposing him to full triplet toxicity, and keeps encorafenib/cetuximab available exactly where its evidence is strongest, at progression. Given his renal function and anticoagulation, full-intensity FOLFOXIRI was already going to need real dose modification regardless of which side of this debate we land on.
Agreed: de-escalated FOLFOX with renal dose adjustment as first-line therapy, with formal geriatric assessment repeated at eight weeks and a low threshold to move to encorafenib plus cetuximab at the first sign of progression or unacceptable toxicity, rather than completing a fixed number of cycles regardless of tolerance.
Not agreed: the geriatric oncologist's preference for starting encorafenib/cetuximab immediately, bypassing chemotherapy entirely, was not adopted — the team judged the off-label first-line evidence too thin to lead with, but recorded the position explicitly as one to revisit quickly if V.P. does not tolerate even the de-escalated chemotherapy backbone.